The Modifiers That Impact Response to the PARP Inhibitor Rucaparib from TRITON2 - Wassim Abida

March 19, 2021

Wassim Abida, MD, PhD, and colleagues presented an abstract titled, "Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC)" at the 2021 ASCO GU Cancers Symposium.  Dr. Wasim Abida joins Charles Ryan, MD highlighting the data that was presented, providing further insight on genomic alterations that impact clinical response to PARP inhibitors based upon this recent analysis.  

Biographies:

Wassim Abida, MD, Ph.D. Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Charles J. Ryan, MD, The B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation, Minneapolis, Minnesota


Read the Full Video Transcript